PILA PHARMA AB

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company recently participated in a review of their Half-Year Financial Report with Direkt Studios, where CEO Gustav H. Gram highlighted their low burn-rate, prudent capital allocation, and the successful rights issue to fund obesity studies using their unique TRPV1-inhibitor. PILA PHARMA is financially well-positioned and preparing to initiate studies in obesity. The company's TRPV1 antagonist, XEN-D0501, has shown promise in preclinical and clinical trials for obesity, diabetes, erythromelalgia, and abdominal aorta aneurysm. PILA PHARMA focuses on treatments for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm, with ongoing and planned studies to evaluate the efficacy and safety of XEN-D0501. The company is also open to out-licensing opportunities for some projects.

PILA PHARMA AB, a Swedish biotech firm, announced its CEO's participation in a new podcast episode discussing the company's oversubscribed rights issue, which aims to fund the development of a novel TRPV1 inhibitor for obesity studies. The podcast highlights PILA PHARMA's strategy in the growing obesity market and the potential impact of their oral drug solution. The company is advancing its TRPV1 inhibitor, XEN-D0501, through clinical trials for obesity and type 2 diabetes, focusing on safety and efficacy. PILA PHARMA also explores applications for erythromelalgia and abdominal aorta aneurysm, seeking partnerships for further development. The company is listed on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition for treating obesity and diabetes. The company is hosting a live online event on August 27, 2025, where CEO Gustav H. Gram will discuss the company's Half-Year Financial Report and the outcome of a recent rights issue and directed issue. The event will be streamed live and recorded for later viewing, with opportunities for questions via email or chat. PILA PHARMA is developing the TRPV1 antagonist XEN-D0501, which has shown promise in treating obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. The company is preparing for further clinical trials to evaluate the safety and efficacy of XEN-D0501. Obesity and diabetes are significant global health issues, with obesity often leading to type 2 diabetes and associated health complications. Erythromelalgia is a rare disease causing pain and redness, while abdominal aorta aneurysm is a cardiovascular condition with no current preventive treatment. PILA PHARMA is collaborating with Uppsala University on research related to abdominal aorta aneurysm.

PILA PHARMA AB announced the completion of a rights issue of units, which included shares and warrants, as well as additional directed issues to underwriters. This process increased the company's total shares by 14,957,792 and its share capital by SEK 639,537.411461, resulting in a dilution effect of approximately 55.14%. The warrants issued allow holders to subscribe for additional shares at a later date, potentially increasing the total share count further. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with ongoing clinical trials and research collaborations. The company also explores treatments for erythromelalgia and abdominal aorta aneurism. The press release includes legal disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, announced that the last day for trading in paid subscribed units related to its rights issue is expected to be on August 5, 2025. The new shares are anticipated to begin trading on Nasdaq First North Growth Market on August 11, 2025. PILA PHARMA focuses on developing TRPV1 antagonists, including XEN-D0501, for treating obesity and type 2 diabetes. The company has completed two phase 2a clinical trials indicating the compound's safety and efficacy. Future plans include further clinical trials and potential treatments for erythromelalgia and abdominal aorta aneurism. The company is involved in a research collaboration with Uppsala University and has received orphan drug designation for XEN-D0501. Legal restrictions apply to the distribution of this press release in certain jurisdictions, and it does not constitute an offer for securities. The announcement includes forward-looking statements subject to risks and uncertainties.

PILA PHARMA AB has completed a rights issue of units, with a directed issue of 487,500 units to underwriters as compensation, priced at SEK 2.00 per unit. This aims to fulfill contractual obligations and improve the company's financial position. The Compensation Issue will increase the number of shares by 487,500 and the share capital by SEK 20,843.617032, resulting in a 1.2% dilution effect. If all warrants are exercised, the number of shares will further increase by 975,000, leading to a 1.4% total dilution effect. The warrants allow subscription for new shares between February 5-15, 2026, at a price between SEK 1.50 and SEK 3.00 per share. PILA PHARMA is a Swedish biotech company focused on developing treatments for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurism, with its candidate XEN-D0501 showing promising results. The press release includes legal restrictions on its distribution and emphasizes the forward-looking nature of the statements.

PILA PHARMA AB announced the final results of its rights issue involving up to 9,994,019 units, each comprising one share and one warrant of series TO2. The rights issue was oversubscribed, with 7,890,774 units subscribed via unit rights and applications for 21,441,385 units without unit rights, totaling approximately 293.49% of the issue. This will provide the company with approximately SEK 20 million before costs, with potential for an additional SEK 60 million upon full exercise of the warrants. Due to oversubscription, the company will conduct an over-allotment issue of up to 4,476,273 units, potentially raising an additional SEK 8.95 million, and up to SEK 26.85 million upon full exercise of the warrants. The rights issue will increase the number of shares from 27,126,623 to 37,120,642, with further increases possible upon warrant exercise. The last trading day for the paid subscribed units is expected to be August 6, 2025, with new shares trading on Nasdaq First North Growth Market from August 12, 2025. PILA PHARMA is a Swedish biotech company focused on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with its development candidate XEN-D0501. The company has completed two phase 2a clinical trials and is preparing for the next trial, PP-CT03, to evaluate the safety and efficacy of XEN-D0501.

PILA PHARMA AB is conducting a rights issue of units, with the last day for subscription being 15 July 2025, although some banks have set an earlier deadline of 14 July. The rights issue involves a maximum of 9,994,019 units, with each unit comprising one newly issued share and one warrant of series TO2. The subscription price is SEK 2.00 per unit, and the warrants allow for the subscription of additional shares between 5 February 2026 and 15 February 2026 at a price based on the market average, with a minimum of SEK 1.50 and a maximum of SEK 3.00 per share. The issue is nearly fully covered by commitments from shareholders and guarantees. If oversubscribed, an additional allotment may be issued. The company is a Swedish biotech firm focusing on TRPV1 antagonists for treating obesity and type 2 diabetes. Their development candidate, XEN-D0501, has shown promise in clinical trials, and they are preparing for further studies. The press release includes legal disclaimers and forward-looking statements, emphasizing that the information provided is not exhaustive and should not be relied upon for investment decisions.

On July 10, 2025, PILA PHARMA AB concludes trading in unit rights related to its rights issue, resolved on June 19, 2025. The rights issue involves up to 9,994,019 units, with 19 unit rights allowing subscription for seven units, each priced at SEK 2.00. Each unit includes one new share and a warrant, enabling subscription for two new shares between February 5-15, 2026, at a price based on market averages, but not less than SEK 1.50 or more than SEK 3.00. The subscription period runs from July 1-15, 2025, with existing shareholders and management committing SEK 10.22 million, covering 51.12% of the issue, and additional guarantees of SEK 9.75 million, totaling 99.87% coverage. An over-allotment option of up to 4,963,773 units may be exercised if oversubscribed. PILA PHARMA, a Swedish biotech firm, focuses on developing TRPV1 antagonists for treating obesity and type 2 diabetes, with ongoing clinical trials and research collaborations. The company also explores applications for erythromelalgia and abdominal aorta aneurism. The press release includes disclaimers about distribution restrictions and forward-looking statements.

PILA PHARMA AB, a Swedish biotech company, is developing novel oral drugs based on TRPV1 inhibition to treat obesity and diabetes. The company participated in a podcast to discuss its proprietary TRPV1 inhibitor's potential in obesity studies and its ongoing rights issue, which is nearly fully covered by existing investors. The funds raised will support obesity studies aimed at creating a comprehensive data package for potential partnerships. PILA PHARMA focuses on developing drugs for obesity, type 2 diabetes, erythromelalgia, and abdominal aorta aneurysm. The company has conducted successful phase 2a trials with its TRPV1 antagonist, XEN-D0501, showing good tolerability and efficacy in enhancing insulin response and reducing cardiovascular biomarkers. PILA PHARMA plans to progress into longer clinical trials and is preparing for a new trial to evaluate XEN-D0501's safety and efficacy in obesity and diabetes. The company also explores treatments for erythromelalgia and abdominal aorta aneurysm, with ongoing research collaborations and plans for proof-of-concept studies.